How effective are adult bone marrow-derived stem cells in treating acute myocardial infarction (AMI)?
Limitations of the trials included sample sizes, clinical hetero.geneity, lack of more patient-centred outcomes (eg, quality of life) and lack of standardisation of outcome assessment methods. Mortality rates after successful revascularisation of the culprit arteries are very low, and, therefore, a larger number of partici.pants would be required to assess the full clinical effect of this treatment. The stem cell harvest and the isolation of the stem/ progenitor cells accounted for 10% of the total costs of the trials. Consequently, this treatment is only currently available in research-associated facilities.
Stem cell therapy offers a promising approach to the regeneration of damaged vascular and cardiac tissue after an AMI.